SCHEMBL16636565

SCHEMBL16636565

COC(=O)C1CCCCC1c1csc(C2CC(F)(F)C2)n1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 1/20 0.39
CNR2 P34972 1/20 0.36
KDM1A O60341 1/20 0.33
ALDH1A1 P00352 1/20 0.32
FABP4 P15090 2/20 0.32
FABP5 Q01469 2/20 0.32
CPT2 P23786 1/20 0.31
CPT1A P50416 1/20 0.31
TMIGD3 P0DMS9 1/20 0.31
ADORA1 P30542 1/20 0.31
SCN9A Q15858 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.30
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636564 1.00 SLC6A2 (0.39) SLC6A2SLC6A4CNR2KDM1AALDH1A1
SCHEMBL16636090 0.85 ALDH1A1 (0.37) KDM1AALDH1A1FABP4FABP5SCN9A
SCHEMBL16636392 0.84 SLC6A2 (0.39) SLC6A2SLC6A4CNR2ALDH1A1CPT2
SCHEMBL16636390 0.84 SLC6A2 (0.39) SLC6A2SLC6A4CNR2ALDH1A1CPT2
SCHEMBL16636099 0.79 SLC6A2 (0.45) SLC6A2SLC6A4CNR2ALDH1A1CPT2
SCHEMBL16635696 0.78 CTSB (0.42) SLC6A2SLC6A4KDM1AALDH1A1LMNA
SCHEMBL16635697 0.78 CTSB (0.42) SLC6A2SLC6A4KDM1AALDH1A1LMNA
SCHEMBL16635693 0.77 SLC6A2 (0.36) SLC6A2SLC6A4CNR2
SCHEMBL16635691 0.77 SLC6A2 (0.36) SLC6A2SLC6A4CNR2
SCHEMBL16635783 0.74 SLC6A2 (0.46) SLC6A2SLC6A4CPT1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SLC6A2 4308/4885SLC6A4 4386/4885CNR2 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.